Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...
GlobalData on MSN5d
EC approves GSK’s Jemperli-chemo combo for endometrial cancerThe European Commission (EC) has approved GSK's Jemperli (dostarlimab) combined with chemotherapy that includes carboplatin ...
GSK’s Jemperli is designed to help the body’s immune system find and attack cancer cells, and is already approved in the EU ...
Jemperli was approved for similar expanded use in endometrial cancer in the United States in August 2024. The drug is also approved for second-line endometrial cancer and dMMR recurrent or ...
London: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy ...
Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...
GSK (GSK) announced the European Commission has approved Jemperli, or dostarlimab, in combination with chemotherapy for first-line treatment of ...
GSK plc (LSE/NYSE: GSK) today announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...
European Commission approved GSK's Jemperli with chemotherapy for advanced or recurrent endometrial cancer, covering 75% of cases. RUBY trial showed Jemperli combo reduced death risk by 31% and ...
European regulators have expanded the usage of GSK's Jemperli drug for endometrial cancer, the pharmaceutical firm announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback